| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mulberrofuran G targets multiple pathways involved in oxidative stress, inflammation, and viral infection. It inhibits NOX4-mediated ROS generation and endoplasmic reticulum stress, protecting against ischemic injury-induced cell death. It is a dual inhibitor of PTP1B and α-glucosidase. It also inhibits the interaction between SARS-CoV-2 spike protein and ACE2 receptor.
|
|---|---|
| ln Vitro |
Mulberrofuran G shows moderate activity against hepatitis B virus (HBV), inhibiting HBV DNA replication with an IC₅₀ of 3.99 μM. It protects cells from ischemic injury-induced cell death by inhibiting NOX4-mediated ROS generation and endoplasmic reticulum stress. It exhibits strong antioxidant activity and inhibits PTP1B and α-glucosidase.
|
| ln Vivo |
Mulberrofuran G has been studied for its antiviral and protective effects in vivo. It has been shown to protect against ischemic injury and to have potential antiviral activity against SARS-CoV-2 by blocking the interaction between the spike protein and the ACE2 receptor. Its anti-inflammatory and antioxidant properties suggest potential benefits in various disease models.
|
| Enzyme Assay |
For non-cellular assays, mulberrofuran G's antioxidant activity can be evaluated using DPPH radical scavenging, ABTS, and FRAP assays. Its inhibition of NOX4 activity can be assessed using a lucigenin-based chemiluminescence assay. Inhibition of PTP1B and α-glucosidase can be measured using chromogenic substrate assays. Binding to the SARS-CoV-2 spike protein can be assessed using surface plasmon resonance (SPR).
|
| Cell Assay |
In vitro cellular assays for mulberrofuran G involve treating cells with the compound and measuring its effects on oxidative stress, inflammation, and viral infection. The compound's protection against ischemic injury is assessed in cell models of oxygen-glucose deprivation. Its antiviral activity against HBV is assessed in HBV-replicating cell lines by measuring viral DNA levels. Its anti-inflammatory effects are assessed by measuring cytokine production.
|
| Animal Protocol |
In vivo animal experiments with mulberrofuran G involve administering the compound to animal models of ischemic injury, viral infection, or inflammation. In models of ischemic stroke, animals are treated with mulberrofuran G, and infarct size and neurological deficits are assessed. In models of viral infection, the compound's effects on viral load and disease progression are evaluated.
|
| ADME/Pharmacokinetics |
Mulberrofuran G has a molecular weight of 562.6 and a molecular formula of C₃₄H₂₆O₈. It is a solid at room temperature and is typically stored at 2-8°C, where it remains stable for up to 24 months. Purity is ≥98%. The compound is soluble in DMSO and other organic solvents. It is protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Toxicological data for mulberrofuran G are limited as it is a natural product research compound. As a natural flavonoid, it is generally considered to have low toxicity, but high doses may cause adverse effects. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Albanol A is an organic heteropentacyclic compound belonging to the 1-benzofuran class. Morus furan G has been reported in mulberry (Morus lhou) and white mulberry (Morus alba), and relevant data are available.
Mulberrofuran G is a natural prenylated flavonoid from mulberry with antioxidant, anti-inflammatory, anticancer, and antiviral properties. It inhibits NOX4-mediated ROS generation, PTP1B and α-glucosidase, and the SARS-CoV-2 spike-ACE2 interaction. It also inhibits HBV replication. The compound is available from various commercial suppliers for research applications. |
| Molecular Formula |
C34H26O8
|
|---|---|
| Molecular Weight |
562.57
|
| Exact Mass |
562.162
|
| CAS # |
87085-00-5
|
| PubChem CID |
9959532
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
695.1±55.0 °C at 760 mmHg
|
| Flash Point |
374.2±31.5 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.745
|
| LogP |
6.75
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
42
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=C[C@@H]2[C@@H]3[C@@H](C1)C4=C(C=C(C=C4)O)O[C@@]3(OC5=CC(=CC(=C25)O)C6=CC7=C(O6)C=C(C=C7)O)C8=C(C=C(C=C8)O)O
|
| InChi Key |
MJJWBJFYYRAYKU-OPKNDJPNSA-N
|
| InChi Code |
InChI=1S/C34H26O8/c1-16-8-23-22-6-4-21(37)15-30(22)41-34(25-7-5-19(35)13-26(25)38)33(23)24(9-16)32-27(39)10-18(12-31(32)42-34)28-11-17-2-3-20(36)14-29(17)40-28/h2-7,9-15,23-24,33,35-39H,8H2,1H3/t23-,24-,33-,34+/m0/s1
|
| Chemical Name |
(1S,9R,13R,21S)-1-(2,4-dihydroxyphenyl)-17-(6-hydroxy-1-benzofuran-2-yl)-11-methyl-2,20-dioxapentacyclo[11.7.1.03,8.09,21.014,19]henicosa-3(8),4,6,11,14,16,18-heptaene-5,15-diol
|
| Synonyms |
NSC-649229; NSC 649229; Mulberrofuran G
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~88.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7776 mL | 8.8878 mL | 17.7756 mL | |
| 5 mM | 0.3555 mL | 1.7776 mL | 3.5551 mL | |
| 10 mM | 0.1778 mL | 0.8888 mL | 1.7776 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
